Search company, investor...
Turning Point Therapeutics company logo

Turning Point Therapeutics

tptherapeutics.com

Founded Year

2013

Stage

Acq - P2P | Acquired

Total Raised

$144.43M

Valuation

$0000 

About Turning Point Therapeutics

Turning Point Therapeutics (TPTX: NASDAQ) is a clinical-stage oncology company for the discovery and development of medicines for cancer and other diseases. The company was founded in 2013 and is based in San Diego, California. In August 2022, Turning Point Therapeutics was acquired by Bristol-Myers Squibb.1B.

Headquarters Location

10628 Science Center Drive Suite 200

San Diego, California, 92121,

United States

+1 858 926 5251

Missing: Turning Point Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Turning Point Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Turning Point Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Turning Point Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Turning Point Therapeutics Patents

Turning Point Therapeutics has filed 26 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Experimental cancer drugs
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/20/2020

9/27/2022

Transcription factors, Clusters of differentiation, Experimental cancer drugs, Proteins, Human proteins

Grant

Application Date

8/20/2020

Grant Date

9/27/2022

Title

Related Topics

Transcription factors, Clusters of differentiation, Experimental cancer drugs, Proteins, Human proteins

Status

Grant

Turning Point Therapeutics Frequently Asked Questions (FAQ)

  • When was Turning Point Therapeutics founded?

    Turning Point Therapeutics was founded in 2013.

  • Where is Turning Point Therapeutics's headquarters?

    Turning Point Therapeutics's headquarters is located at 10628 Science Center Drive, San Diego.

  • What is Turning Point Therapeutics's latest funding round?

    Turning Point Therapeutics's latest funding round is Acq - P2P.

  • How much did Turning Point Therapeutics raise?

    Turning Point Therapeutics raised a total of $144.43M.

  • Who are the investors of Turning Point Therapeutics?

    Investors of Turning Point Therapeutics include Bristol-Myers Squibb, Cormorant Asset Management, SR One, Lilly Asia Ventures, OrbiMed Advisors and 9 more.

  • Who are Turning Point Therapeutics's competitors?

    Competitors of Turning Point Therapeutics include Genprex.

Compare Turning Point Therapeutics to Competitors

Mirati Therapeutics Logo
Mirati Therapeutics

Mirati Therapeutics is developing treatment for patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread. Its precision oncology strategy seeks to treat the patients most likely to benefit and is driven by drugs that target very specific genetic mutations that cause cancer and genomic tests that identify patients who carry those driver mutations.

Genprex Logo
Genprex

Genprex is a privately held, clinical-stage biopharmaceutical company developing nanovesicle therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. The company's pan-kinase inhibitors work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways. These biologic therapies target key oncogenic pathways to treat tumors and cancer metastases at the molecular level without harming normal cells. Used in combination with other targeted therapies, these drugs overcome genomic limitations inherent with targeted therapies including tyrosine kinase inhibitory drugs (TKIs). Genprex technologies also can be used to reduce drug resistance in patients with intrinsic or acquired drug resistance. Its products will broadly participate in the global oncology marketplace by addressing the unmet medical needs of cancer patients and expanding populations of patients benefiting from our combination treatments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.